Concepedia

Deborah M. Gurner

DM

Statistics

Publications

8

Citations

526

H-Index

8

Active since

1996

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Stellenbosch University

Pontificia Universidad Católica de Chile

Harvard University

University of Auckland

Deborah M. Gurner is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacy, and osteoporosis.

Publications per year

1996–2019

8

Publications

8

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

, , +10

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma

Carlos A. Camargo, Deborah M. Gurner, Howard Smithline et al. · Journal of Allergy and Clinical Immunology · 2010 · 85 citations · Full text

, , +8

Independent Origin of Mono-Rifampin-Resistant Mycobacterium Tuberculosis in Patients With AIDS

Michael Lutfey, Phyllis Della‐Latta, Vivek Kapur et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 67 citations

, , +15

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

Sydney Lou Bonnick, Tobias De Villiers, Alberto Odio et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 59 citations

, , +14

Intermittent or daily montelukast versus placebo for episodic asthma in children

Erkka Valovirta, María Lina Boza, Colin F. Robertson et al. · Annals of Allergy Asthma & Immunology · 2011 · 53 citations

, , +11

1–5 of 8